Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies

Bibliography

• SERRUYS PW, DE JAEGERE P, KIEMENEIJ F et al, for the Benestent Study Group: A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl. J. Med. (1994) 331:489–495.
   PubMed Web of Science ®Google Scholar
• AL SUWAIDI J, HOLMES DR Jr, SALAM AM et al.: Impact of coronary artery stent on mortality and non fatal MI: meta-analysis of randomised trials comparing a strategy of routine stenting with that of balloon angioplasty. Am. Heart J. (2004) 147(5):756–758.
   PubMedGoogle Scholar
• LANE DM: Dramatic increase in use if coronary stents [letter]. Am. J. Cardiol (1999) 84:1141.
   PubMedGoogle Scholar
• POPMA JJ, OHMAN EM, WEITZ Jet al.: Antiplatelet therapy in patients undergoing percutaneous coronary intervention. Chest (2001) 119:32-36S.
   Google Scholar
• SCHOMIG A, NEUMANN FJ, KASTRATI A et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl. J. Med. (1996) 224:1084–1089.
   Google Scholar
• LEON MB, BAIM DS, POPMA JJ et al, for the Stent Anticoagulation Resetenosis Study Investigators: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl. J. Med. (1998) 339:1665–1671.
   PubMed Web of Science ®Google Scholar
• •The first paper definitely assessing antithrombotic-drug regimens for coronary artery stents.
   Google Scholar
• WILSON SH, RIHAL CS, BELL MR et al.: Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am. J. Cardiol. (1999) 83:1006–1011.
   PubMed Web of Science ®Google Scholar
• SCHOHLEN H, KASTRATI A, PACHE J et al.: Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5678 patients with a four-week ticlopidine regimen. J. Am. Coll. Cardiol. (2001) 37:2066–2073.
   PubMedGoogle Scholar
• VAN DOMBURG RT, FOLEY DP, DE FEYTER PJ et al.: Long-term clinical outcome after coronary balloon angioplasty: identification of a population at low risk of recurrent events during 17 years of follow-up. Eur. Heart J. (2001) 22:934–941.
   Google Scholar
• HANNAN EL, RACZ MJ, ARANI DT et al.: A comparison of short- and long-term outcomes for balloon angioplasty and coronary stent placement. J. Am. Coll. Cardiol. (2000) 36:395–403.
   PubMed Web of Science ®Google Scholar
• METHA S, YUSUF S, PETERS R et ed.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527-533. Pretreatment of clopidogrel precoronary stenting is critically important.
   Google Scholar
• STEINHUBL SR, BERGER PB, MANN JT et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized trial. /AMA (2002) 288:2411-2420. Supports long-term oral antiplatelet therapy following percutaneous intervention.
   Google Scholar
• SHAKNOVICH A: Complications of coronary stenting. Coron. Artery Dis. (1994) 5:583–589.
   PubMed Web of Science ®Google Scholar
• MCNICHOL A, ISRAELS SJ: Platelets andanti-platelet therapy. J. Pharmacot Sci. (2003) 93:381–396.
   PubMedGoogle Scholar
• PATRONO C, BACHMANN F, BAIGENT C et al.: Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur. Heart J. (2004) 25:166–181.
   Google Scholar
• GAWAZ M, NEUMANN FJ, OTT A, SCHOMIG A: Platelet activation and coronary stent implantation. Circulation (1996) 94:279–285.
   PubMed Web of Science ®Google Scholar
• BARNATHAN ES, SCHWARTZ JS, TAYLOR Let al.: Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation (1987) 76:125–134.
   Google Scholar
• SCHWARTZ L, BOURASSA MG, LESPERANCE J et al.: Aspirin and dipyrklamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engt J. Med. (1988) 318:1714–1719.
   PubMed Web of Science ®Google Scholar
• FISCHMAN DL, LEON MB, BAIM DS et at, for the Stent Restenosis Study Investigators: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl. J. Med. (1994) 331:496–501.
   PubMed Web of Science ®Google Scholar
• MAX K-H, BELLI G, ELLIS SG et al.: Subacute stent thrombosis: evolving issues and current concepts. J. Am. Coll. Cardiol. (1996) 27:494–503.
   PubMedGoogle Scholar
• STEINBUHL SR, LAUER MS, MUKHERJEE DP et al.: The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarction. J. Am. Coll. Cardiol. (1998) 32:1366–1370.
   PubMedGoogle Scholar
• STEINHUBL SR, ELLIS SG, WOLSKI K et al.: Ticlopidine pre-treatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/Illa Inhibitor for Stenting (EPISTENT) Trial. Circulation (2001) 103:1403–1409.
   PubMed Web of Science ®Google Scholar
• CHEW DP, BHATT DL, ROBBINS MA et al.: Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reacitve protein. Am. J. Cardiol. (2001) 88:672–674.
   PubMed Web of Science ®Google Scholar
• THE EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein IIb/Illa blockade. Lancet (1998) 352:87–92.
   PubMed Web of Science ®Google Scholar
• O'SHEA JC, HAFLEY GE, GREENBERG S et al.: Platelet glycoproteinintegrein blockadewith eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. /AMA (2001) 285:2468–2473.
   Google Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br. Med. J. (2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• PATRIGNANI P, FILABOZZI P, PATRONO C: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects./ Clin. Invest. (1982) 69:1366–1372.
   Google Scholar
• WEKSLER BB, PETT SB, ALONSO D et al.: Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl. J. Med. (1983) 308:800–805.
   PubMed Web of Science ®Google Scholar
• PATRONO C, COLLAR B, DALEN J et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest (1998) 114:470S–488S.
   Google Scholar
• MUFSON L, BLACK A, ROUBIN G et al.: A randomized trial of aspirin in PTCA: effect of high versus low dose aspirin on major complications and restenosis. J. Am. Coll. Cardiol. (1998) 80\(Suppl. 2):II-64 (Abstract).
   Google Scholar
• SMITH SC Jr, DOVE JT, JACOBS AK et al.: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation (2001) 103:3019–3041.
   PubMedGoogle Scholar
• PETERS RJG, MEHTA SR, FOX KAA et al.: Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndrome: observations from the CURE study. Circulation (2003) 108:1682–1687.
   PubMedGoogle Scholar
• MARTIN J, QUINN MD, DESMOND J, FITZGERALD MD: Ticlopidine and Clopidogrel. Circulation (1999) 100:1667–1672.
   PubMedGoogle Scholar
• COUKELL AJ, MARKHAM A: Clopidogrel. Drugs (1997) 54:745–750.
   PubMed Web of Science ®Google Scholar
• SAVCIC M, HAUERT J, BACHAMANN F et al.: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. (1999) 2(Suppl.):15–19.
   Google Scholar
• THEBAULT JJ, BLATRIX CE, BLANCHARD JF, PANAK EA: The interactions of ticlopidine and aspirin in normal subjects. J. Int. Med. Res. (1977) 5:405–411.
   PubMedGoogle Scholar
• VAN DE LOO A, NAUCK M, NOORY E, JUST H, WOLLSCHLAGER H: Enhancement of platelet inhibition of ticlopidine plus aspirin versus aspirin alone given prior to elective PTCA. Eur. Heart J. (1998) 19:96–102.
   PubMedGoogle Scholar
• BETRAND ME, LEGRAND V, BOLAND Jet al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation (1998) 98:1597–1603.
   Google Scholar
• HALL P, NAKAMURA S, MAIELLO L et al.: A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation (1996) 93:215–222.
   PubMed Web of Science ®Google Scholar
• URBAN P, MACAYA C, RUPPRECHT H-J et aL: Randomized evaluation of anticoagulation in hight risk patients. The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation (1998) 98:2126–2132.
   Google Scholar
• MCTAVISH D, FAULDS D, GOA KL: Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet dependent disorders. Drugs (1990) 40:238–259.
   PubMedGoogle Scholar
• MULLER C, BUTTNER HJ, PETERSEN J, ROSKAMM H: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation (2000) 101:590–593.
   PubMed Web of Science ®Google Scholar
• MOUSSA I, OETGEN M, ROUBIN G et al.: Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation (1999) 99:2364–2366.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, RUPPRECHT H-J, URBAN PU, GERSHLOCK AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation (2000) 102:624–629.
   PubMedGoogle Scholar
• TANIUCHI M, KRUZ HI, LASALA JM:Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation (2001) 104:539–543.
   PubMed Web of Science ®Google Scholar
• BERGER PB, BELL MR, HASDAI D, GRILL DE, MELBY S, HOLMES DR: Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation (1999) 99:248–253.
   PubMedGoogle Scholar
• GILLS, MAJUMDAR S, BROWN NE, ARMSTONG PW: Ticlopidine-associated pancytopenia: implication of an acetylsalicylic acid alternative. Can. J. CardioL (1997) 13:909–913.
   PubMedGoogle Scholar
• SZTO GY, LINNEMEIER TJ, BALL MW: Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am. J. CardioL (1999) 83:138–139.
   PubMed Web of Science ®Google Scholar
• PAGE Y, TARDY B, ZENI F, COMTET C, TERRANA R, BERTRAND JC: Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet (1991) 337:774–776.
   PubMed Web of Science ®Google Scholar
• CARPIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMedGoogle Scholar
• RICCCIARDI MJ, DAVIDSON CJ, KNOW K, BENNETT CL: Active pharmacovigilance efforts compared to the FDA's Medwatch drug surveillance program for the detection of ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura. J. Am. Coll. Cardiol. (2001) 37(Suppl. A):506A.
   Google Scholar
• KLEIN LW, CALVIN LE: Use of clopidogrel in coronary stenting: what was the question?J. Am. Coll. CardioL (1999) 34:1895–1898.
   PubMedGoogle Scholar
• BERGER PB, BELL MR, RIHAL CS et aL:Clopidogrel versus ticlopidine after intracoronary stent placement. J. Am. Coll. Cardiol. (1999) 34:1891–1894.
   PubMed Web of Science ®Google Scholar
• MISHKEL GJ, AQUIRRE FV, LIGON RW, ROCHA-SINGH KJ, LUCORE CL: Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J. Am. Coll. Cardiol. (1999) 34:1884–1890.
   PubMed Web of Science ®Google Scholar
• CALVER AL, BLOWS LJ, HARMER S et aL: Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents. Am. Heart J. (2000) 140:483–491.
   PubMedGoogle Scholar
• DANGAS G, MEHRAN R, ABIZIAD AS et aL: Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am. J. Cardiol. (2001) 87:470–472.
   PubMedGoogle Scholar
• BHATT DL, BETRAND ME, BERGER PB et aL: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. CardioL (2002) 39:9–14.
   PubMed Web of Science ®Google Scholar
• CHEW DP, BHATT DL, SAPP S et aL: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a Meta analysis of Phase III multicenter randomized trials. Circulation (2001) 103:210–216.
   Google Scholar
• TOPOL EJ, EASTON JD, AIVIARENCO P et aL: Randomized, double-blind, placebo-controlled, international trial of the oral IIb/Illa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation (2003) 108:399–406.
   PubMed Web of Science ®Google Scholar
• MCKEE SA, SANE DC, SELOARGYRIS EN: Aspirin resistance in cardiovascular disease: a review of prevalence, mechanism and clinical significance. Thromb. Haemost. (2002) 88:711–715.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, HIRSH J WEITZ JI et aL: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 105:1650–1655.
   PubMed Web of Science ®Google Scholar
• GUM PA, KOTTKE-MARCHANT K, WELSH PA et aL: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. CardioL (2003) 41:961–965.
   PubMed Web of Science ®Google Scholar
• CHEN W-H, LEE P-Y, NG W et aL: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pre-treatment. J. Am. Coll. CardioL (2004) 43:1122–1126.
   PubMedGoogle Scholar
• VANE JR, BAKHLE YS, BOTTING RM: Cyclooxygenase 1 and 2. Ann. Rev. PharmacoL lbxicol. (1998) 38:97–120.
   PubMed Web of Science ®Google Scholar
• BINDER CS, STUDENT LA, BONAN JL et aL: Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood. (1993) 82:505–512.
   PubMedGoogle Scholar
• LIBBY P, SIMON DI: Inflammation and thrombosis: the clot thickens. Circulation (2001) 103:1718–1720.
   PubMed Web of Science ®Google Scholar
• ANDRE P, NANNIZZI-ALAIMO L, PRASAD SK, PHILLIPS DR: Platelet derived CD4OL: the switch-hitting player of cardiovascular disease. Circulation (2002) 106:896–899.
   PubMed Web of Science ®Google Scholar
• HERMANN A, RAUCH BH, BRAUN M et al.: Platelet CD40 ligand - subcellular localisation, regulation of expression, and inhibition by clopidogrel. Platelets (2001) 12:74–82.
   PubMed Web of Science ®Google Scholar
• CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N EngL J. Med. (2001) 345:1809–1817.
   PubMed Web of Science ®Google Scholar
• HOWARD PA, DELAFONTAINE P.: Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J. Am. Coll. CardioL (2004) 43:519–525.
   PubMed Web of Science ®Google Scholar
• MOBLEY JE, BRESEE SJ, WORTHAM DC, CRAFT RM, SNIDER CC, CARROLL RC: Frequency of nonresponse antiplatelet activity of clopidogrel during pre-treatment for cardiac catheterisation. Am. J. CardioL (2004) 93:456–458.
   PubMed Web of Science ®Google Scholar
• GRUBEL PA, BLINDEN KP, HIATT BL, O'CONNOR CM: Clopidogrel for coronary stenting. Response variability, drug resistance and the effect of pre-treatment platelet reactivity. Circulation (2003) 107:2908–2913.
   Google Scholar
• LAU WC, GURBEL PA, WATKINS PB et aL: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 109:166–171.
   PubMed Web of Science ®Google Scholar
• FONTANA P, DUPONT A, GANDRILLE S et al.: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation (2003) 108:989–995.
   PubMed Web of Science ®Google Scholar
• LEPANTALO A, VIRTANEN KS, HEIKKILA J et aL: Limited early antiplatelet effect of 300mg clopidogrel in patients with aspirin therapy undergoing coronary interventions. Eur. Heary. (2004) 25:476–483.
   PubMed Web of Science ®Google Scholar
• MATEZTZKY S, SHENKMAN B, GUETTA Vet aL: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109:3171–3175.
   PubMedGoogle Scholar
• LAU WC, GURBEL PA, WATKINS PB et aL: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 109:166–171.
   PubMed Web of Science ®Google Scholar
• LAU WC, WASKELL LA, WATKINS PB et aL: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107:32–37.
   PubMed Web of Science ®Google Scholar
• WIENBERGEN H, GITT AK, SCHIELE R et aL: Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndrome taking atorvstatin versus other stain therapies. Am. J. CardioL (2003) 92:285–288.
   PubMed Web of Science ®Google Scholar
• FONTANA P, DUPONT A, GANRILEE Set al.: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variation in healthy subjects. Circulation (2003) 108:989–995.
   Google Scholar
• THE TASK FORCE ON THE MANAGEMENT OF ACUTE CORONARY SYNDROMES OF THE EUROPEAN SOCIETY OF CARDIOLOGY: The task force report: The management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heary. (2002) 23:1809–1840.
   PubMedGoogle Scholar
• YUSUF S, ZHAO F, MEHTA SR et cll.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N EngL Med. (2001) 345:494–502.
   Google Scholar
• CANNON C, WEINTRAUB W, DEMOPOULOS Let aL: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein inhibitor tirofiban. N EngL J. Med. (2001) 334:1879–1887.
   Google Scholar
• STEINHUBL SR, DARRAH S, BRENNAN D et aL: Optimal duration of pre-treatment with clopidogrel prior to PCI: data from the CREDO trial. Circulation (2003) 108:IV–374.
   Google Scholar
• VAN DER HEIJDEN DJ, WESTENDORP ICD, RIEZEBOS RK et al.: Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J. Am. Coll. CardioL (2004) 44:20–24.
   Google Scholar
• SAVCIC M, HAUERT J, BACHAMANN F et al.: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. (1999) 2 (Suppl.):15–19.
   Google Scholar
• MOLLER I, SEYFARTH M, RUDIGER S et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. (2001) 85:92–93.
   PubMed Web of Science ®Google Scholar
• PACHE J, KASTRATI A, MEHILL Jet al.: Clopidogrel therapy in patients undergoing coronary stenting: value of a high loading dose regimen. Catheter Cardiovasc. Interv. (2002) 55(4):436–444.
   Google Scholar
• KASTRATI A, MEHILL J, SCHOHLEN H et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pre-treatment with clopidogrel. N EngL J. Med. (2004) 350:232–238.
   PubMed Web of Science ®Google Scholar
• BHATT DL, TOPOL EJ: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J. (2004) 148:263–268.
   PubMed Web of Science ®Google Scholar
• SADANANDAN S, CANNON CP, GIBSON M, MURPHY SA, DIBATTISTE PM, BRAUNWALD E: A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. (2004) 44:799–803.
   PubMed Web of Science ®Google Scholar
• WALLENTIN L, LAGERQVIST B, HUSTED S et al.: Outcome at 1 year after an invasive compared to a non-invasive strategy in coronary-artery disease: FRSIC II invasive randomised trial. Lancet (2000) 356:9–16.
   PubMed Web of Science ®Google Scholar
• YENDE S, WUNDERINK RG: Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit. Care Med. (2001) 29:2271–2275.
   PubMed Web of Science ®Google Scholar
• HONGO RH, LEY J, DICK SE et aL: The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J. Am. Coll. CardioL (2002) 40:231–237.
   PubMed Web of Science ®Google Scholar
• FOX KAA, MEHTA SR, PETERS R et al.: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome. The CURE trial. Circulation (2004) 110:1202–1208.
   PubMedGoogle Scholar
• LEW R, AJANI A. WAKSMAN R: Review of intracoronary radiation for in-stent restenosis. J. Invasive CardioL (2003) 15(Suppl. A):2A–8A.
   Google Scholar
• WAKSMAN R: Late thrombosis after radiation: sitting on a time bomb. Circulation (1999) 100:780-782.11 Expert Opin. Pharmacother (2005) 6(1)
   Google Scholar
• WAKSMAN R, AJANI AE, WHITE RL et al.: Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary y-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial Plus 6 months of clopidogrel (WRIST PLUS). Circulation (2001) 103:2332–2335.
   PubMed Web of Science ®Google Scholar
• WAKSMAN R, AJANI AE, PINNOW E et al.: Twelve versus six months of clopidogrel ti reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation (2002) 106:776–778.
   PubMed Web of Science ®Google Scholar
• JENKINS NP, PRENDERGAST BD, THOMAS M: Drug eluting coronary stents. Br. Med. J. (2002) 325:1315–1316.
   PubMed Web of Science ®Google Scholar
• FATTORI R, PIVA T: Drug-eluting stents in vascular intervention. Lancet (2003) 361:247–249.
   PubMed Web of Science ®Google Scholar
• HILL RA, DONDAR Y, BAKHAI A, DICKSON R, WALLEY T: Drug-eluting stents: an early systemic review to inform policy. Eur. Heart J. (2004) 25:902–919.
   PubMed Web of Science ®Google Scholar
• JEREMIAS A, SYLVA B, BRIDGES Jet al.: Stent thrombosis after successfid sirolimus-eluting stent implantation. Circulation (2004) 109:1930–1932.
   Google Scholar
• KERNER A, GRUBERG L, KAPELIOVICH M et al.: Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc. Interv. (2003) 60:505–508.
   PubMed Web of Science ®Google Scholar
• LEMOS PA, SERRUYS PW, VAN DOMBURG RT et al.: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the real world: the Rapamycin-Eluting Stent Evaluated At Totterdam Cardiology Hospital (RESEARCH) registry. Circulation (2004) 109:190–195.
   Google Scholar
• MCFADDEN E, STABILE E, REGAR E et al.: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 364:1519–1521.
   PubMed Web of Science ®Google Scholar
• •An interesting observation of late thrombosis with drug-eluting stents.
   Google Scholar
• STONE GW, ELLIS SG, RUSSELL ME: Paclitaxel-eluting coronary stents. N Engl. J. Med. (2004) 350:2099–2100.
   PubMedGoogle Scholar
• ••Drug-eluting stents have revolutionisedinterventional cardiology practice.
   Google Scholar